C-MER Medical (HKG:3309) expects a loss attributable to equity holders between HK$130 million and HK$160 million in 2024, against a profit of HK$62 million logged in 2023, a Wednesday Hong Kong bourse filing said.

The company attributed the expected swing to loss to certain impairments on goodwill, property, plant, equipment, and the group's right-of-use assets resulting from weaker performance from some hospitals, market competition, and a weakened consumer sentiment.